Table 1 Clinico-pathological features of patient cohort
| Â | Type I EC |
|---|---|
|  | (n = 116) |
Age (years) | Â |
<65 | Â |
≥65 |  |
Histoligical type | Â |
Enodometrioid adenocarcinoma | 102 (87.9%) |
Adenosquamouse carcinoma | 14 (12.1%) |
WHO Grade | Â |
G1 | 34 (29.3%) |
G2 | 59 (50.9%) |
G3 | 23 (19.8%) |
Tumor size | Â |
1 | 86 (74.1%) |
2 | 14 (12.1%) |
3 | 14 (12.1%) |
4 | 2 (1.7%) |
LN status | Â |
Negative | 95 (81.9%) |
Positive | 14 (12.1%) |
Unknown | 7 (6.0%) |
Metastases | Â |
Negative | 79 (68.1%) |
Positive | 7 (6.0%) |
Unknown | 30 (25.9%) |
Lymphagiosis | Â |
Negative | 24 (20.7%) |
Positive | 26 (22.4%) |
Unknown | 66 (56.9%) |
FIGO stage | Â |
I | 51 (44.0%) |
II | 7 (6.0%) |
III | 24 (20.7%) |
IV | 10 (8.6%) |
Unknown | 24 (20.7%) |
Postoperative therapy | Â |
No therapy | 35 (30.2%) |
Brachytherapy | 41 (35.3%) |
Radiotherapy | 28 (24.2%) |
Chemotherapy | 2 (1.7%) |
Chemotherapy & radiotherapy | 6 (5.2%) |
Unknown | 4 (3.4%) |
Recurrent EC and outcome | Â |
EC recurrent | 17 (14.7%) |
EC related death | 9 (7.8%) |
Other related death | 1 (0.9%) |
Further-on follow up | 7 (6.0%) |